Guanfacine 1 TAKEDA, guanfacine (as hydrochloride) 1 mg modified release tablet blister pack

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

guanfacine hydrochloride, Quantity: 1.14 mg

Available from:

Takeda Pharmaceuticals Australia Pty Ltd

Pharmaceutical form:

Tablet, modified release

Composition:

Excipient Ingredients: hypromellose; methacrylic acid - ethyl acrylate copolymer (1:1); sodium lauryl sulfate; polysorbate 80; microcrystalline cellulose; colloidal anhydrous silica; lactose; povidone; crospovidone; glycerol dibehenate; fumaric acid

Administration route:

Oral

Units in package:

28, 7

Prescription type:

(S4) Prescription Only Medicine

Therapeutic indications:

indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6-17 years old, as monotherapy (when stimulants or atomoxetine are not suitable, not tolerated or have been shown to be ineffective) or as adjunctive therapy to psychostimulants (where there has been a sub-optimal response to psychostimulants). must be used as part of a comprehensive ADHD management programme, typically including psychological, educational and social measures.

Product summary:

Visual Identification: Round, white to off-white tablets and debossed with '1MG' on one side and '503' on the other side.; Container Type: Blister Pack; Container Material: PVC/PCTFE (Aclar)/Al; Container Life Time: 4 Years; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Authorization status:

Registered

Authorization date:

2022-12-02